Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul 11;4(7):e225.
doi: 10.1038/bcj.2014.48.

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

R Bassan  1 , O Spinelli  2 , E Oldani  2 , T Intermesoli  2 , M Tosi  2 , B Peruta  2 , E Borlenghi  3 , E M Pogliani  4 , E Di Bona  5 , V Cassibba  6 , A M Scattolin  7 , C Romani  8 , F Ciceri  9 , A Cortelezzi  10 , G Gianfaldoni  11 , D Mattei  12 , E Audisio  13 , A Rambaldi  2
Affiliations

Different molecular levels of post-induction minimal residual disease may predict hematopoietic stem cell transplantation outcome in adult Philadelphia-negative acute lymphoblastic leukemia

R Bassan et al. Blood Cancer J. .
No abstract available

PubMed Disclaimer

Figures

Figure 1
Figure 1
Outcomes by quantitative MRD ranges. Shown are long-term survival, DFS and RI rates according to MRD quantitative ranges and SCT therapy (6-year probability is given for each group). (a–c) All patients with MRD study (n=136): CMR (n=64) 0.73, 0.63, 0.36; MR (n=21) 0.57, 0.52, 0.33; MR1 (n=17) 0.53, 0.47, 0.50; MR2 (n=34), 0.24, 0.15, 0.76. (d–f), MRD+ patients receiving allo/auto-SCT (n=43): MR/MR1 (n=24) 0.50, 0.46, 0.43; MR2 (n=19) 0.26, 0.16, 0.69. (g–i) MRD+ patients receiving allo-SCT (n=26): MR/MR1 (n=15) 0.60, 0.60, 0.23; MR2 (n=11), 0.27, 0.18, 0.64.
See this image and copyright information in PMC

References

    1. Bruggemann M, Raff T, Kneba M. Has MRD monitoring superseded other prognostic factors in adult ALL. Blood. 2012;120:4470–4481. - PubMed
    1. Bassan R, Spinelli O, Oldani E, Intermesoli T, Tosi M, Peruta B, et al. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL) Blood. 2009;113:4153–4162. - PubMed
    1. Gokbuget N, Kneba M, Raff T, Trautmann H, Bartram CR, Arnold R, et al. Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies. Blood. 2012;120:1868–1876. - PubMed
    1. Ribera JM, Oriol A, Morgades M, Montesinos P, Sarrà J, González-Campos J, et al. Treatment of high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in adolescents and adults according to early cytologic response and minimal residual disease after consolidation assessed by flow cytometry: final results of PETHEMA ALL-HR-03. J Clin Oncol. 2014;32:1595–1604. - PubMed
    1. Spinelli O, Peruta B, Tosi M, Guerini V, Salvi A, Zanotti MC, et al. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007;92:612–618. - PubMed

LinkOut - more resources